• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data
    • FAQs

Publications

Science

Science

  • SCYNEXIS Research Platform
  • Publications and Presentations
    • Publications
    • Posters and Presentations
  • Expanded Access
  • Publications and Presentations

  • Publications
  • Posters and Presentations
Clear Search

Ibrexafungerp: A Novel Oral Glucan Synthase Inhibitor

M R Davis, M A Donnelley, G R Thompson
Medical Mycology
July 2019

A novel 1,3-beta-D-glucan inhibitor, Ibrexafungerp (formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Larkin L, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Ghannoum M
Antimicrobial Agents and Chemotherapy
March 2019

SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.

Wring S, Borroto-Esoda K, Solon E, Angulo D
Antimicrobial Agents and Chemotherapy
January 2019

Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.
Clinical Pharmacology in Drug Development
June 2018

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.
Journal of Clinical Pharmacology
May 2018

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Schell WA, Jones AM, Borroto-Esoda K, Alexander B
Antimicrobial Agents and Chemotherapy
November 2017

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations that both Overlap and are Distinct from those Conferring Echinocandin Resistance

Jimenez-Ortigosa C, Perez WB, Angulo D, Borroto-Esoda K, Perlin DS
Antimicrobial Agents and Chemotherapy
September 2017

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-resistant Strains of Candida Species

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M
Antimicrobial Agents and Chemotherapy
August 2017

In vitro Activity of Novel Glucan Synthase Inhibitor SCY-078 against Clinical Isolates of Candida auris

Berkow EL, Angulo D, Lockhart SR
Antimicrobial Agents and Chemotherapy
July 2017

The Novel Oral Glucan Synthase Inhibitor SCY-078 shows In vitro Activity against Sessile and Planktonic Candida spp

Marcos-Zambrano LJ, Gomez-Perosanz M, Escribano P, Bouza E, Guinea
Journal of Antimicrobial Chemotherapy
July 2017

  • « Previous
  • 1
  • 2
  • 3
  • Next »

1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
View Google Map

© 2021 SCYNEXIS, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us